
1. nature. 2015 jun 18;522(7556):315-20. doi: 10.1038/nature14451.

a novel multiple-stage antimalarial agent inhibits protein synthesis.

baragaña b(1), hallyburton i(1), lee mc(2), norcross nr(1), grimaldi r(1), otto
td(3), proto wr(3), blagborough am(4), meister s(5), wirjanata g(6), ruecker
a(4), upton lm(4), abraham ts(2), almeida mj(2), pradhan a(7), porzelle a(1),
luksch, martínez ms(8), luksch t, bolscher jm(9), woodland a(1), norval s(1),
zuccotto f(1), thomas j(1), simeons f(1), stojanovski l(1), osuna-cabello m(1),
brock pm(4), churcher ts(4), sala ka(4), zakutansky se(4), jiménez-díaz mb(8),
sanz lm(8), riley j(1), basak r(2), campbell m(10), avery vm(11), sauerwein
rw(9), dechering kj(9), noviyanti r(12), campo b(13), frearson ja(1),
angulo-barturen i(8), ferrer-bazaga s(8), gamo fj(8), wyatt pg(1), leroy d(13),
siegl p(13), delves mj(4), kyle de(7), wittlin s(14), marfurt j(6), price rn(15),
sinden re(4), winzeler ea(5), charman sa(10), bebrevska l(13), gray dw(1),
campbell s(13), fairlamb ah(1), willis pa(13), rayner jc(3), fidock da(16), read 
kd(1), gilbert ih(1).

author information: 
(1)drug discovery unit, division biological chemistry drug discovery,
college life sciences, university dundee, dundee dd1 5eh, uk.
(2)department microbiology immunology, columbia university college of
physicians surgeons, new york, new york 10032, usa.
(3)malaria programme, wellcome trust sanger institute, wellcome trust genome
campus, cambridge cb10 1sa, uk.
(4)department life sciences, imperial college, london sw7 2az, uk.
(5)university california, san diego, school medicine, 9500 gilman drive
0760, la jolla, california 92093, usa.
(6)global health tropical medicine division, menzies school health
research, charles darwin university, po box 41096, casuarina, darwin, northern
territory 0811, australia.
(7)department global health, college public health university south
florida, 3720 spectrum boulevard, suite 304, tampa, florida 33612, usa.
(8)glaxosmithkline, tres cantos medicines development campus-diseases the
developing world, severo ochoa 2, tres cantos 28760, madrid, spain.
(9)tropiq health sciences, geert grooteplein 28, huispost 268, 6525 ga nijmegen, 
the netherlands.
(10)centre drug candidate optimisation, monash university, 381 royal parade, 
parkville, victoria 3052, australia.
(11)eskitis institute, brisbane innovation park, nathan campus, griffith
university, queensland 4111, australia.
(12)malaria pathogenesis laboratory, eijkman institute molecular biology,
jalan diponegoro 69, 10430 jakarta, indonesia.
(13)medicines malaria venture, po box 1826, 20 route de pre-bois, 1215 geneva
15, switzerland.
(14)swiss tropical public health institute, socinstrasse 57, 4051 basel,
switzerland.
(15)1] global health tropical medicine division, menzies school health
research, charles darwin university, po box 41096, casuarina, darwin, northern
territory 0811, australia [2] centre tropical medicine global health,
nuffield department medicine, university oxford, oxford ox3 7lj, uk.
(16)1] department microbiology immunology, columbia university college 
physicians surgeons, new york, new york 10032, usa [2] division infectious
diseases, department medicine, columbia university college physicians and
surgeons, new york, new york 10032, usa.

erratum in
    nature. 2016 sep 1;537(7618):122.

comment in
    nat rev microbiol. 2015 aug;13(8):458.
    nat rev drug discov. 2015 aug;14(8):527.

there urgent need new drugs treat malaria, broad therapeutic
potential novel modes action, widen scope treatment to
overcome emerging drug resistance. describe discovery ddd107498, a
compound potent novel spectrum antimalarial activity against
multiple life-cycle stages plasmodium parasite, good pharmacokinetic 
properties acceptable safety profile. ddd107498 demonstrates potential 
address variety clinical needs, including single-dose treatment,
transmission blocking chemoprotection. ddd107498 developed a
screening programme blood-stage malaria parasites; molecular target
has identified translation elongation factor 2 (eef2), is
responsible gtp-dependent translocation ribosome along messenger
rna, essential protein synthesis. discovery eef2 viable
antimalarial drug target opens new possibilities drug discovery.

doi: 10.1038/nature14451 
pmcid: pmc4700930
pmid: 26085270  [indexed medline]

